221 related articles for article (PubMed ID: 8979268)
1. The amino terminus of Cdk2 binds p21.
Moskowitz NK; Borao FJ; Dardashti O; Cohen HD; Germino FJ
Oncol Res; 1996; 8(9):343-52. PubMed ID: 8979268
[TBL] [Abstract][Full Text] [Related]
2. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.
Chen IT; Akamatsu M; Smith ML; Lung FD; Duba D; Roller PP; Fornace AJ; O'Connor PM
Oncogene; 1996 Feb; 12(3):595-607. PubMed ID: 8637717
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H.
Higashi H; Suzuki-Takahashi I; Saitoh S; Segawa K; Taya Y; Okuyama A; Nishimura S; Kitagawa M
Eur J Biochem; 1996 Apr; 237(2):460-7. PubMed ID: 8647086
[TBL] [Abstract][Full Text] [Related]
4. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
[TBL] [Abstract][Full Text] [Related]
5. Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity.
Kriwacki RW; Hengst L; Tennant L; Reed SI; Wright PE
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11504-9. PubMed ID: 8876165
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop.
Garrett S; Barton WA; Knights R; Jin P; Morgan DO; Fisher RP
Mol Cell Biol; 2001 Jan; 21(1):88-99. PubMed ID: 11113184
[TBL] [Abstract][Full Text] [Related]
7. Regulation of cyclin A-Cdk2 by SCF component Skp1 and F-box protein Skp2.
Yam CH; Ng RW; Siu WY; Lau AW; Poon RY
Mol Cell Biol; 1999 Jan; 19(1):635-45. PubMed ID: 9858587
[TBL] [Abstract][Full Text] [Related]
8. The effects of changing the site of activating phosphorylation in CDK2 from threonine to serine.
Kaldis P; Cheng A; Solomon MJ
J Biol Chem; 2000 Oct; 275(42):32578-84. PubMed ID: 10931829
[TBL] [Abstract][Full Text] [Related]
9. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors.
Adams PD; Sellers WR; Sharma SK; Wu AD; Nalin CM; Kaelin WG
Mol Cell Biol; 1996 Dec; 16(12):6623-33. PubMed ID: 8943316
[TBL] [Abstract][Full Text] [Related]
10. Regulation of CAK kinase activity by p53.
Schneider E; Montenarh M; Wagner P
Oncogene; 1998 Nov; 17(21):2733-41. PubMed ID: 9840937
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta targeted inactivation of cyclin E:cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity.
Nagahara H; Ezhevsky SA; Vocero-Akbani AM; Kaldis P; Solomon MJ; Dowdy SF
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):14961-6. PubMed ID: 10611320
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-binding motifs are essential for the function of p21CIP1.
Chen J; Saha P; Kornbluth S; Dynlacht BD; Dutta A
Mol Cell Biol; 1996 Sep; 16(9):4673-82. PubMed ID: 8756624
[TBL] [Abstract][Full Text] [Related]
13. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
14. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
Gong J; Ammanamanchi S; Ko TC; Brattain MG
Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668
[TBL] [Abstract][Full Text] [Related]
16. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.
Coats S; Whyte P; Fero ML; Lacy S; Chung G; Randel E; Firpo E; Roberts JM
Curr Biol; 1999 Feb; 9(4):163-73. PubMed ID: 10074425
[TBL] [Abstract][Full Text] [Related]
17. TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase.
Ono T; Kitaura H; Ugai H; Murata T; Yokoyama KK; Iguchi-Ariga SM; Ariga H
J Biol Chem; 2000 Oct; 275(40):31145-54. PubMed ID: 10878006
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
[TBL] [Abstract][Full Text] [Related]
19. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver.
Albrecht JH; Poon RY; Ahonen CL; Rieland BM; Deng C; Crary GS
Oncogene; 1998 Apr; 16(16):2141-50. PubMed ID: 9572495
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
Orend G; Hunter T; Ruoslahti E
Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
